Brain 18F-FDG-PET: Utility in the diagnosis of dementia and epilepsy

Eyal Lotan*, Kent P. Friedman, Tima Davidson, Timothy M. Shepherd

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


The authors reviewed the two most common current uses of brain 18F-labeled fluoro-2-deoxyglucose positron emission tomography (FDG-PET) at a large academic medical center. For epilepsy patients considering surgical management, FDG-PET can help localize epileptogenic lesions, discriminate between multiple or discordant EEG or MRI findings, and predict prognosis for post-surgical seizure control. In elderly patients with cognitive impairment, FDG-PET often demonstrates lobar-specific patterns of hypometabolism that suggest particular underlying neurodegenerative pathologies, such as Alzheimer’s disease. FDG-PET of the brain can be a key diagnostic modality and contribute to improved patient care.

Original languageEnglish
Pages (from-to)178-184
Number of pages7
JournalIsrael Medical Association Journal
Issue number3
StatePublished - Mar 2020


  • Alzheimer’s disease
  • Dementia
  • Epilepsy
  • F-labeled fluoro-2-deoxyglucose positron emission tomography (FDG-PET)


Dive into the research topics of 'Brain 18F-FDG-PET: Utility in the diagnosis of dementia and epilepsy'. Together they form a unique fingerprint.

Cite this